Compare RVSN & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RVSN | LEXX |
|---|---|---|
| Founded | 2016 | 2004 |
| Country | Israel | Canada |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.1M | 18.9M |
| IPO Year | 2022 | N/A |
| Metric | RVSN | LEXX |
|---|---|---|
| Price | $5.71 | $0.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.50 |
| AVG Volume (30 Days) | 199.3K | ★ 204.2K |
| Earning Date | 11-28-2025 | 01-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $776,000.00 | $522,000.00 |
| Revenue This Year | $28.46 | $13.35 |
| Revenue Next Year | $755.09 | $78.83 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 5.05 |
| 52 Week Low | $3.66 | $0.46 |
| 52 Week High | $29.57 | $1.91 |
| Indicator | RVSN | LEXX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Rail Vision Ltd is a development-stage technology company that is engaged in the design, development, and assembly of railway detection systems designed to solve the challenges in railway operational safety, efficiency, and predictive maintenance. Its railway detection systems include different types of cameras, including optics, visible light spectrum cameras (video), and thermal cameras that transmit data to a ruggedized onboard computer which is designed to be suitable for the rough environment of a train's locomotive. It has developed its railway detection and systems to save lives, increase efficiency, and dramatically reduce expenses for the railway operator.
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.